These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9296233)

  • 1. Impact of a vancomycin restriction policy on use and cost of vancomycin and incidence of vancomycin-resistant Enterococcus.
    Morgan AS; Brennan PJ; Fishman NO
    Ann Pharmacother; 1997 Sep; 31(9):970-3. PubMed ID: 9296233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of pharmacy policies designed to limit inappropriate vancomycin use: a population-based assessment.
    Thomas AR; Cieslak PR; Strausbaugh LJ; Fleming DW
    Infect Control Hosp Epidemiol; 2002 Nov; 23(11):683-8. PubMed ID: 12452297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a vancomycin restriction policy on ordering practices during an outbreak of vancomycin-resistant Enterococcus faecium.
    Anglim AM; Klym B; Byers KE; Scheld WM; Farr BM
    Arch Intern Med; 1997 May; 157(10):1132-6. PubMed ID: 9164379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limiting vancomycin use to combat vancomycin-resistant Enterococcus faecium.
    Belliveau PP; Rothman AL; Maday CE
    Am J Health Syst Pharm; 1996 Jul; 53(13):1570-5. PubMed ID: 8809278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of increased colonization with vancomycin-resistant enterococci during preferential use of vancomycin for treatment during an outbreak of healthcare-associated Clostridium difficile infection.
    Miller M; Bernard L; Thompson M; Grima D; Pepin J
    Infect Control Hosp Epidemiol; 2010 Jul; 31(7):710-5. PubMed ID: 20518636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative cost-effectiveness of alternative empiric antimicrobial treatment options for suspected enterococcal bacteremia.
    McComb MN; Collins CD
    Pharmacotherapy; 2014 Jun; 34(6):537-44. PubMed ID: 24390863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure to eradicate vancomycin-resistant enterococci in a university hospital and the cost of barrier precautions.
    Lai KK; Kelley AL; Melvin ZS; Belliveau PP; Fontecchio SA
    Infect Control Hosp Epidemiol; 1998 Sep; 19(9):647-52. PubMed ID: 9778162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of a multifaceted infection control policy in reducing vancomycin usage and vancomycin-resistant enterococci at a tertiary care cancer centre.
    Shaikh ZH; Osting CA; Hanna HA; Arbuckle RB; Tarr JJ; Raad II
    J Hosp Infect; 2002 May; 51(1):52-8. PubMed ID: 12009821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Vancomycin resistant enterococci in Austria].
    Allerberger F; Lass-Flörl C; Dierich MP; Hirschl AM; Presterl E; Haas G; Klare I; Witte W
    Wien Klin Wochenschr; 1997 May; 109(9):312-20. PubMed ID: 9265389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vancomycin-resistant enterococcus in end-stage renal disease.
    Brady JP; Snyder JW; Hasbargen JA
    Am J Kidney Dis; 1998 Sep; 32(3):415-8. PubMed ID: 9740157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does vancomycin prescribing intervention affect vancomycin-resistant enterococcus infection and colonization in hospitals? A systematic review.
    de Bruin MA; Riley LW
    BMC Infect Dis; 2007 Apr; 7():24. PubMed ID: 17425800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment options for vancomycin-resistant enterococcal infections.
    Linden PK
    Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Third-generation cephalosporins and vancomycin as risk factors for postoperative vancomycin-resistant enterococcus infection.
    Dahms RA; Johnson EM; Statz CL; Lee JT; Dunn DL; Beilman GJ
    Arch Surg; 1998 Dec; 133(12):1343-6. PubMed ID: 9865653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vancomycin-resistant Enterococcus in liver transplant patients.
    Orloff SL; Busch AM; Olyaei AJ; Corless CL; Benner KG; Flora KD; Rosen HR; Rabkin JM
    Am J Surg; 1999 May; 177(5):418-22. PubMed ID: 10365883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology and control of vancomycin-resistant enterococci in an adult and children's hospital.
    Tucci V; Haran MA; Isenberg HD
    Am J Infect Control; 1997 Oct; 25(5):371-6. PubMed ID: 9343618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The incidence of and clinical variables associated with vancomycin-resistant enterococcal colonization in mechanically ventilated patients.
    Bhorade SM; Christenson J; Pohlman AS; Arnow PM; Hall JB
    Chest; 1999 Apr; 115(4):1085-91. PubMed ID: 10208212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure to develop vancomycin-resistant Enterococcus with oral vancomycin treatment of Clostridium difficile.
    Salgado CD; Giannetta ET; Farr BM
    Infect Control Hosp Epidemiol; 2004 May; 25(5):413-7. PubMed ID: 15188848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of vancomycin-resistant Enterococcus bloodstream infections in southern Taiwan.
    Chou CH; Lee NY; Lee HC; Chang CM; Lee CC; Ko WC
    J Microbiol Immunol Infect; 2012 Jun; 45(3):221-7. PubMed ID: 22578639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality.
    Lautenbach E; Bilker WB; Brennan PJ
    Infect Control Hosp Epidemiol; 1999 May; 20(5):318-23. PubMed ID: 10349947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vancomycin-resistant enterococcal infections in Korea.
    Kim JM; Song YG
    Yonsei Med J; 1998 Dec; 39(6):562-8. PubMed ID: 10097684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.